BioPlus Acquisition Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

R. Ross Haghighat

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Geen updates

Recent updates

CEO

R. Ross Haghighat (59 yo)

no data

Tenure

Mr. R. Ross Haghighat serves as the Chief Executive Officer of Elecon, Inc. He serves as Chairman of the Board at FRX Innovations Inc. Mr. Haghighat is Managing Partner of Triton Systems, Inc., and Newbury...

BioPlus Acquisition Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Recent updates

BioPlus Acquisition Corp. Files Form 15

BioPlus Acquisition Corp.(NasdaqGM:BIOS) dropped from NASDAQ Composite Index

Avertix Medical, Inc. terminated the acquisition of BioPlus Acquisition Corp. (NasdaqGM:BIOS) from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others in a reverse merger transaction.

BioPlus Acquisition Corp. (NasdaqGM:BIOS) entered into a definitive merger agreement to acquire Avertix, Inc. for approximately $170 million.

BioPlus Acquisition Corp. has completed an IPO in the amount of $200 million.

CEO

Tenure